Pharmaceuticals

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Outlook: Growth and Forecast Highlights 2030

February 16, 2026February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market be in 2030 compared with 2026?

The market size for human epidermal growth factor receptor 2 (her2)-positive gastric cancer has exhibited steady growth in recent years. Projections indicate it will expand from $1.31 billion in 2025 to $1.37 billion in 2026, driven by a compound annual growth rate (CAGR) of 4.6%. Historically, this growth can be attributed to several factors including the limited availability of targeted therapies, a reliance on conventional chemotherapy and radiation therapy, low awareness of her2-positive gastric cancer, restricted access to specialty clinics, and the slow adoption of immunotherapy.

The market for human epidermal growth factor receptor 2 (her2)-positive gastric cancer is projected to experience consistent expansion over the upcoming years, with its size anticipated to reach $1.64 billion by 2030, progressing at a compound annual growth rate (CAGR) of 4.6%. Several factors are expected to fuel this expansion during the projection period, including the emergence of innovative antibody-drug conjugates, a rise in clinical trials focusing on her2-targeted treatments, improvements in healthcare infrastructure within developing economies, advancements in precision medicine and biomarker testing, and the proliferation of ambulatory surgery centers and specialized oncology clinics. Key trends characterizing this forecast timeframe involve the growing acceptance of her2-targeted therapies, a heightened understanding of different gastric cancer subtypes, broader application of immunotherapy and monoclonal antibodies, an increase in customized treatment strategies, and a stronger emphasis on early diagnosis and screening.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25787&type=smp

What Drivers Are Guiding Growth Patterns In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

The growing acceptance of targeted cancer therapy is anticipated to propel the expansion in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market moving forward. This treatment approach, also referred to as personalized medicine, employs specific drugs or substances to impede cancer growth by concentrating on particular molecules involved in tumor development. The uptick in targeted therapy usage is largely attributable to advancements in genetic profiling, which facilitate more precise treatments based on an individual’s unique tumor characteristics, leading to improved efficacy and fewer side effects. For HER2-positive gastric cancer, targeted therapy operates by directly attacking the HER2 protein, which is overexpressed in these tumors, thereby slowing disease progression and improving patient outcomes. For instance, in February 2024, the Food and Drug Administration (FDA) approved 16 new personalized medicines, including 7 drugs for cancer and 3 for various other diseases and conditions in 2023, signifying an increase from 6 in 2022, according to the Personalized Medicine Coalition, a US-based professional membership organization. Therefore, the escalating adoption of targeted cancer therapy is fueling the growth of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market.

How Is The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Divided Into Segments?

The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market covered in this report is segmented –

1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy

2) By Stage: Stage I, Stage II, Stage III, Stage IV

3) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users

Subsegments:

1) By Chemotherapy: Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines

2) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies

3) By Radiation Therapy: External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy

4) By Targeted Therapy: HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors

What Trends Are Driving The Growth Trajectory Of The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

Major companies engaged in the HER2-positive gastric cancer market are primarily focused on securing approvals for innovative treatments, such as advanced immunotherapy-enhanced combination regimens. These regimens involve integrating immune checkpoint inhibitors with targeted therapy and chemotherapy, with the goal of substantially improving patient outcomes in first-line treatment settings. This advanced immunotherapy-enhanced combination strategy harnesses the body’s immune system by blocking programmed death (PD)-1 or programmed death (PD)-L1 interaction while simultaneously targeting HER2 receptors and utilizing chemotherapeutic agents, thereby amplifying anti-tumor activity and boosting survival rates. For instance, in March 2025, Merck & Co., Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for pembrolizumab (Keytruda) in combination with trastuzumab and chemotherapy. This approval is for the first-line treatment of adults with HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express programmed death (PD)-L1. This newly approved combination therapy demonstrated a considerable improvement in median progression-free survival and overall survival compared to standard regimens. With a higher overall response rate of 73% and a longer median duration of response, this treatment signifies a paradigm shift in managing advanced HER2-positive gastric cancers.

Which Major Industry Participants Are Leading The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Growth?

Major companies operating in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/human-epidermal-growth-factor-receptor-2-her2-positive-gastric-cancer-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25787&type=smp

Browse Through More Reports Similar to the Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market 2026, By The Business Research Company

Gastric Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Cancer Diagnostic Procedure Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastric-cancer-diagnostic-procedure-global-market-report

Intestine Cancer Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info